A team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and the Urologic Tumours Unit of the Institut Català d'Oncologia (ICO) and the Germans Trias i Pujol Research ...
Recombinant human ACE2 as a novel biotherapeutic for the treatment of patients with cancer. Background: EGFR-TKI is one of the most important treatments of NSCLC patients, but not all patients ...
A phase I/II study of C019199 in combination with sintilimab in advanced malignancy. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback